Chugai Pharmaceutical Co.... (CHGCY)
Company Description
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng.
It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases.
Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia.
The company was founded in 1925 and is headquartered in Tokyo, Japan.
Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
| Country | JP |
| IPO Date | Aug 3, 2012 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 5,026 |
| CEO | Dr. Osamu Okuda |
Contact Details
Address: Nihonbashi Mitsui Tower Tokyo, JP | |
| Website | https://www.chugai-pharm.co.jp |
Stock Details
| Ticker Symbol | CHGCY |
| Exchange | PNK |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001453934 |
| CUSIP Number | 171269103 |
| ISIN Number | US1712691039 |
| Employer ID | 00-0000000 |
| SIC Code |
Key Executives
| Name | Position |
|---|---|
| Dr. Osamu Okuda | President, Chief Executive Officer & Chairman |
| Iwaaki Taniguchi | Executive Vice President, Head of Finance Supervisory Division, Chief Financial Officer & Director |
| Dr. Tomoyuki Igawa Ph.D. | Vice President & Head of Research Division |
| Junichi Ebihara | Executive Vice President |
| Junichi Takano | Head of Marketing & Sales Division |
| Kosuke Iijima | Head of PHC Solution Department |
| Shinji Hidaka | Executive Vice President |
| Tetsuya Yamaguchi | Executive Vice President |
| Toshiya Sasai | Executive of Investor Relations Group & Corporate Communications Department |
| Yoshiyuki Yano | Executive Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 02, 2020 | F-6 POS | Filing |
| Nov 22, 2019 | F-6EF | Filing |
| Sep 27, 2017 | F-6EF | Filing |
| Jan 14, 2009 | F-6EF | Filing |